Optimizing Outcomes When Treating Glabellar Lines
Aesthet Surg J
.
2023 Jun 14;43(7):786-788.
doi: 10.1093/asj/sjad087.
Authors
Nowell Solish
,
Vince Bertucci
,
Jeremy B Green
,
Michael A C Kane
PMID:
37217827
PMCID:
PMC10371039
DOI:
10.1093/asj/sjad087
No abstract available
MeSH terms
Botulinum Toxins, Type A*
Double-Blind Method
Forehead / surgery
Humans
Neuromuscular Agents*
Patient Satisfaction
Skin Aging*
Treatment Outcome
Substances
Botulinum Toxins, Type A
Neuromuscular Agents
Grants and funding
Revance Therapeutics
Oxford University Press